Purple Biotech Ltd
TASE:PPBT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Purple Biotech Ltd
Other Liabilities
Purple Biotech Ltd
Other Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
Purple Biotech Ltd
TASE:PPBT
|
Other Liabilities
$160k
|
CAGR 3-Years
3%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-1%
|
|
|
Teva Pharmaceutical Industries Ltd
TASE:TEVA
|
Other Liabilities
$4.1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
9%
|
CAGR 10-Years
13%
|
|
|
Sol Gel Technologies Ltd
NASDAQ:SLGL
|
Other Liabilities
$935k
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
|
|
PolyPid Ltd
NASDAQ:PYPD
|
Other Liabilities
$3.6m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
80%
|
CAGR 10-Years
N/A
|
|
|
Mediwound Ltd
NASDAQ:MDWD
|
Other Liabilities
$8.8m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-10%
|
|
|
R
|
Rekah Pharmaceutical Industry Ltd
TASE:REKA
|
Other Liabilities
₪23.1m
|
CAGR 3-Years
15%
|
CAGR 5-Years
15%
|
CAGR 10-Years
-3%
|
|
Purple Biotech Ltd
Glance View
Purple Biotech Ltd. is a development stage pharmaceutical company, which engages in drug development. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The firm is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.
See Also
What is Purple Biotech Ltd's Other Liabilities?
Other Liabilities
160k
USD
Based on the financial report for Dec 31, 2025, Purple Biotech Ltd's Other Liabilities amounts to 160k USD.
What is Purple Biotech Ltd's Other Liabilities growth rate?
Other Liabilities CAGR 10Y
-1%
Over the last year, the Other Liabilities growth was 14%. The average annual Other Liabilities growth rates for Purple Biotech Ltd have been 3% over the past three years , -10% over the past five years , and -1% over the past ten years .
